Bookmark and Sharºe


1: Arch Cardiol Mex. 2008 Jan-Mar;78(1):52-9.
Evaluacion del efecto de carvedilol en ninos con cardiomiopatia dilatada.
Saucedo, Norma Alicia Balderrabano; Alarcon, Alfredo Vizcaino; Islas, Gonzalo Espinosa; De La Cruz, Lorenzo Reyes;
Hospital Infantil de Mexico Federico Gomez, Mexico, D.F.
OBJECTIVE: To evaluate the effect of carvedilol administrated during 8 months in children with heart failure secondary to dilated cardiomyopathy. METHODS: We initiated carvedilol in patients who, despite optimization of standard treatment, had persistent left ventricular ejection fraction < or = 40% and evaluated the systolic and diastolic left ventricular function before and after 4 and 8 months of treatment. RESULTS: 19 patients were included in the study, 10 women; median age: 6.7 years and 17 ± 12.4 months after the diagnosis. The ejection fraction improved significantly from entry to eight months (median: 33.5 to 52.6%, p = 0.01) as did the shortening fraction (m: 14.8 to 25.8%, p = 0.01). The myocardial performance index abnormal in all 19 patients became normal in 5 at the end of study. In addition mitral Doppler flow which was altered in 9 improved in 3 and pulmonary venous flow abnormal in all patients improved in 13. Only 1 patient presented minimal adverse effects. CONCLUSIONS: Carvedilol added to standard therapy for dilated cardiomyopathy improves left ventricular function, is well tolerated, and has minimal adverse effects in childhood.
  • Femenino
  • Humanos
  • Masculino
  • Niño
  • Adolescentes
  • Preescolar
  • Lactante
  • Estudios Prospectivos
  • Propanolaminas (uso terapéutico)
  • CARBAZOLES (uso terapéutico)
  • Cardiomiopatía Dilatada (quimioterapia)

Pubgle

Buscador de Guías de Práctica Clínica

Enciclopedia Médica

Alerta Bibliográfica